Ionis CEO nets PRSU shares, sells 62,970

Ionis Pharmaceuticals CEO Brett P. Monia reported two stock transactions.

Rhea-AI Filing Summary

Ionis Pharmaceuticals CEO Brett P. Monia reported two stock transactions. On January 29, 2026, he acquired 122,214 shares of common stock at $0.00 upon vesting of performance-based restricted stock units. These PRSUs vested at 167.27% of target, based on Ionis’s relative total shareholder return versus a peer group.

On January 30, 2026, Monia sold 62,970 shares of Ionis common stock at a weighted average price of $82.7216, from multiple trades between $82.26 and $82.925. After these transactions he directly owned 283,927 shares of Ionis common stock.

Insider Trade Summary

Net Seller: 62,970 shares

Net Sell 2 txns

Insider Monia Brett P

Role Chief Executive Officer

Sold 62,970 shs ($5.21M)

Type	Security	Shares	Price	Value
Sale	Common Stock	62,970	$82.7216	$5.21M
Grant/Award	Common Stock	122,214	$0.00	$0.00

Holdings After Transaction: Common Stock — 283,927 shares (Direct)

Footnotes (2)

1. F1. Represents shares earned upon the vesting of performance-based restricted stock units ("PRSUs") for the performance period of the grant to the reporting person reported on January 18, 2023. The Compensation Committee certified achievement of the pre-established performance goal based on the Issuer's relative total shareholder return as compared to a peer group of companies at a level resulting in a vest of 167.27% of target shares. As reported at grant, the PRSUs could result in a payout of 0% to 200% based on actual achievement of the goal.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.26 to $82.925 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Ionis (IONS) CEO Brett Monia report?

Ionis CEO Brett Monia reported acquiring 122,214 common shares from vesting PRSUs on January 29, 2026, then selling 62,970 shares on January 30, 2026 at a weighted average price of $82.7216, leaving him with 283,927 directly held shares.

How did Brett Monia acquire 122,214 Ionis (IONS) shares in January 2026?

Brett Monia acquired 122,214 Ionis shares at $0.00 when performance-based restricted stock units vested. The Compensation Committee certified performance at 167.27% of target, based on Ionis’s relative total shareholder return versus a peer group for the applicable performance period.

At what price did the Ionis (IONS) CEO sell 62,970 shares?

The 62,970 Ionis shares were sold at a weighted average price of $82.7216 per share. Individual trades occurred in multiple transactions at prices ranging from $82.26 to $82.925, as disclosed in the Form 4 transaction footnote.

How many Ionis (IONS) shares does Brett Monia own after these Form 4 trades?

After the reported January 2026 transactions, Brett Monia directly held 283,927 Ionis common shares. This figure reflects both the 122,214-share PRSU vesting and the subsequent 62,970-share sale disclosed in the non-derivative securities table.

What performance goal drove the PRSU vesting for Ionis (IONS) CEO Brett Monia?

The PRSU vesting was based on Ionis’s relative total shareholder return versus a peer group. The Compensation Committee certified achievement at 167.27% of target shares, within a possible payout range from 0% to 200% depending on actual goal attainment.

Were Brett Monia’s sold Ionis (IONS) shares from multiple trades?

Yes. The 62,970 sold shares came from multiple trades aggregated as a weighted average price. Individual sales occurred between $82.26 and $82.925 per share, and full trade-by-trade detail is available upon request to Ionis or the SEC staff.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/02/2026 - 08:51 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Monia Brett P

(Last) (First) (Middle)

2855 GAZELLE COURT

(Street)

CARLSBAD CA 92010

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IONIS PHARMACEUTICALS INC [ IONS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/29/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/29/2026		A		122,214(1)	A	$0.0	346,897	D
Common Stock	01/30/2026		S		62,970	D	$82.7216(2)	283,927	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares earned upon the vesting of performance-based restricted stock units ("PRSUs") for the performance period of the grant to the reporting person reported on January 18, 2023. The Compensation Committee certified achievement of the pre-established performance goal based on the Issuer's relative total shareholder return as compared to a peer group of companies at a level resulting in a vest of 167.27% of target shares. As reported at grant, the PRSUs could result in a payout of 0% to 200% based on actual achievement of the goal.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.26 to $82.925 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

	By: Patrick R. O'Neil, attorney-in-fact For: Brett P. Monia	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.